CIK 0001817241 · <br>Emerging growth company
Artiva Biotherapeutics, Inc.
Sign in to watch- Ticker
- ARTV
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 863614316
- Phone
- (858) 267-4467
- Business address
- 5505 MOREHOUSE DRIVE, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,341,159
- in 16 filings, $529K under 10b5-1 plans
Net −$2,341,159. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-15 | Horan Christopher Chief Tech Operations Officer | Grant or award | +117,300 | 302,639 | ||
| 2026-02-15 | Horan Christopher Chief Tech Operations Officer | Shares withheld for taxes | −2,187 | $4.00 | $9K | 300,452 |
| 2026-02-15 | Bush Jennifer COO, CLO, Secy, Compliance Off | Grant or award | +117,300 | 350,225 | ||
| 2026-02-15 | Bush Jennifer COO, CLO, Secy, Compliance Off | Shares withheld for taxes | −3,515 | $4.00 | $14K | 346,710 |
| 2026-02-15 | Banerjee Subhashis Chief Medical Officer | Grant or award | +102,000 | 152,000 | ||
| 2026-02-15 | Aslan Fred President and CEO | Grant or award | +366,850 | 1,576,798 | ||
| 2026-02-15 | Aslan Fred President and CEO | Shares withheld for taxes | −14,600 | $4.00 | $58K | 1,562,198 |
| 2025-12-15 | Aslan Fred President and CEO | Sale 10b5-1 | −3,187 | $6.00 | $19K | 1,209,948 |
| 2025-12-12 | Raymon Heather SVP, Research and Development | Grant or award | +67,253 | 106,844 | ||
| 2025-12-12 | Raymon Heather SVP, Research and Development | Returned to the company · Employee Stock Option (Right to Buy) | −18,239 | 0 | ||
| 2025-12-12 | Raymon Heather SVP, Research and Development | Returned to the company · Employee Stock Option (Right to Buy) | −12,539 | 0 | ||
| 2025-12-12 | Raymon Heather SVP, Research and Development | Returned to the company · Employee Stock Option (Right to Buy) | −14,819 | 0 | ||
| 2025-12-12 | Raymon Heather SVP, Research and Development | Returned to the company · Employee Stock Option (Right to Buy) | −11,399 | 0 | ||
| 2025-12-12 | Raymon Heather SVP, Research and Development | Returned to the company · Employee Stock Option (Right to Buy) | −10,259 | 0 | ||
| 2025-12-12 | Horan Christopher Chief Tech Operations Officer | Grant or award | +107,156 | 185,339 | ||
| 2025-12-12 | Horan Christopher Chief Tech Operations Officer | Returned to the company · Employee Stock Option (Right to Buy) | −77,519 | 0 | ||
| 2025-12-12 | Horan Christopher Chief Tech Operations Officer | Returned to the company · Employee Stock Option (Right to Buy) | −9,119 | 0 | ||
| 2025-12-12 | Horan Christopher Chief Tech Operations Officer | Returned to the company · Employee Stock Option (Right to Buy) | −20,519 | 0 | ||
| 2025-12-12 | Bush Jennifer COO, CLO, Secy, Compliance Off | Grant or award | +84,877 | 232,925 | ||
| 2025-12-12 | Bush Jennifer COO, CLO, Secy, Compliance Off | Returned to the company · Employee Stock Option (Right to Buy) | −41,039 | 0 |
Page 5 of 11 · 203 trades